Companies Shaping the Cell-Based Immunotherapies Market Companies

The global cell-based immunotherapies market is poised for significant growth, with an estimated value of USD 4.59 billion in 2024. By 2025, this market is expected to reach USD 5.28 billion, and projections show it could hit USD 18.62 billion by 2034, expanding at a compound annual growth rate (CAGR) of 15.02%. This growth is largely driven by the rising incidence of cancer and advancements in immunology and cell engineering. Cell-based therapies, including CAR T-cell and TCR-based treatments, are gaining popularity for their targeted approaches and effectiveness. The market’s expansion is supported by regulatory backing, increasing demand for personalized treatments, and a surge in clinical research.

Key Market Insights

Market Size and Growth:
- Estimated market size in 2024: USD 4.59 billion
- Projected market size by 2034: USD 18.62 billion
- CAGR between 2025 and 2034: 15.02%
Market Segments:
- Therapy Type: CAR-T cell therapy leads the market with a share of 50-55% in 2024. However, the NK cell therapy segment is expected to grow at the fastest CAGR.
- Application: Oncology dominates, with the hematologic malignancies subsegment capturing 60-65% of the market revenue in 2024.
Regional Insights:
- North America held a dominant 45.50% of the market revenue share in 2024.
- The Asia-Pacific region is expected to witness the fastest growth during the forecast period.

Top Companies in the Cell-Based Immunotherapies Market

Novartis AG
- About: Novartis is a global healthcare company with a strong presence in the field of cell-based immunotherapies. Known for its groundbreaking work in CAR-T cell therapy, Novartis continues to lead the market with its innovative therapies.
- Products: Kymriah (Tisagenlecleucel) – a CAR-T cell therapy for various hematologic cancers.
- Market Cap: Approximately USD 200 billion.
Gilead Sciences (Kite Pharma)
- About: Gilead Sciences, through its Kite Pharma division, is a leader in cell-based immunotherapies, particularly in CAR-T therapies. Kite Pharma focuses on treating cancers, particularly blood cancers.
- Products: Yescarta (Axicabtagene Ciloleucel) – a CAR-T therapy used for lymphoma and leukemia.
- Market Cap: Approximately USD 85 billion.
Bristol-Myers Squibb (Juno Therapeutics)
- About: Bristol-Myers Squibb, a major player in the biotechnology industry, owns Juno Therapeutics, which specializes in immuno-oncology and cell therapies. Their research focuses on CAR-T cell and TCR therapies.
- Products: Breyanzi (Lisocabtagene Maraleucel) – a CAR-T therapy for lymphoma.
- Market Cap: Approximately USD 160 billion.
Adaptimmune Therapeutics
- About: Adaptimmune is a leader in developing TCR-based therapies for cancer. The company focuses on enhancing the body’s immune system to recognize and attack cancer cells.
- Products: ADP-A2M4 – an engineered TCR therapy targeting solid tumors.
- Market Cap: Approximately USD 1.5 billion.
Fate Therapeutics
- About: Fate Therapeutics focuses on stem cell-based therapies and cell engineering. The company works to develop novel immune-oncology therapies that can treat a range of cancers.
- Products: FT516 – an NK cell therapy targeting blood cancers.
- Market Cap: Approximately USD 3 billion.
bluebird bio, Inc.
- About: bluebird bio is dedicated to the development of gene therapies, including innovative cell-based immunotherapies for blood disorders and cancer.
- Products: Kymriah (Tisagenlecleucel) – a CAR-T therapy in partnership with Novartis.
- Market Cap: Approximately USD 3.5 billion.
Allogene Therapeutics
- About: Allogene is a biotech company pioneering in allogeneic cell-based therapies. Their work is focused on advancing CAR-T and NK cell therapies.
- Products: ALLO-715 – an allogeneic CAR-T therapy targeting blood cancers.
- Market Cap: Approximately USD 3 billion.
Celyad Oncology
- About: Celyad Oncology is a leader in the development of CAR-T and TCR therapies aimed at solid and hematologic cancers.
- Products: CYAD-101 – a CAR-T therapy targeting solid tumors.
- Market Cap: Approximately USD 250 million.
TCR2 Therapeutics
- About: TCR2 Therapeutics focuses on TCR-based therapies, using the body’s immune system to fight cancers.
- Products: TC-210 – a TCR-based therapy targeting solid tumors.
- Market Cap: Approximately USD 600 million.
Immunocore Limited
- About: Immunocore is a leader in the development of TCR therapies for cancer. Their platform aims to engage the immune system to target and destroy tumors.
- Products: KIMMTRAK (tebentafusp) – a first-in-class TCR therapy for uveal melanoma.
- Market Cap: Approximately USD 2 billion.
Bellicum Pharmaceuticals
- About: Bellicum focuses on developing cell-based immunotherapies, particularly with a focus on CAR-T and TCR therapies.
- Products: BPX-601 – a CAR-T therapy targeting solid tumors.
- Market Cap: Approximately USD 100 million.
Atara Biotherapeutics
- About: Atara Biotherapeutics is a leader in developing T-cell therapies for cancer and autoimmune diseases.
- Products: ATA188 – a T-cell therapy for multiple sclerosis.
- Market Cap: Approximately USD 2.5 billion.
Cellular Biomedicine Group
- About: Cellular Biomedicine Group is focused on advancing cell therapies, including CAR-T and stem cell-based treatments for cancer.
- Products: CG0070 – a gene-modified T-cell therapy for bladder cancer.
- Market Cap: Approximately USD 500 million.
Medigene AG
- About: Medigene is a German biotechnology company specializing in the development of TCR therapies and vaccines for cancer.
- Products: MDG1011 – a TCR therapy targeting multiple cancers.
- Market Cap: Approximately USD 150 million.
Legend Biotech
- About: Legend Biotech is a leader in the development of innovative cell therapies, particularly CAR-T treatments for hematologic cancers.
- Products: LCAR-B38M – a CAR-T therapy for multiple myeloma.
- Market Cap: Approximately USD 6 billion.
Takeda Pharmaceutical Company
- About: Takeda is a global leader in the development of cell-based immunotherapies, with a focus on immune-oncology and cell engineering.
- Products: TAK-007 – a CAR-T therapy targeting blood cancers.
- Market Cap: Approximately USD 50 billion.

The cell-based immunotherapies market is expanding rapidly due to advances in immunology and the increasing demand for personalized cancer treatments. Companies like Novartis, Gilead Sciences, and Bristol-Myers Squibb are at the forefront, leading the development and commercialization of cutting-edge therapies. As clinical research and regulatory support continue to grow, the market is set to experience sustained growth over the next decade.

Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com

FAQs

What are cell-based immunotherapies?
Cell-based immunotherapies are treatments that use the body’s own immune cells to fight diseases like cancer. These therapies include CAR-T and TCR-based treatments.
Which companies dominate the cell-based immunotherapies market?
Leading companies in the market include Novartis, Gilead Sciences (Kite Pharma), Bristol-Myers Squibb, and Adaptimmune Therapeutics.
What is CAR-T cell therapy?
CAR-T cell therapy is a form of immunotherapy that modifies a patient’s T-cells to better recognize and attack cancer cells.
How fast is the cell-based immunotherapies market growing?
The market is projected to grow at a CAGR of 15.02% from 2025 to 2034, reaching an estimated USD 18.62 billion by 2034.
What is the most common application for cell-based immunotherapies?
The most common application for cell-based immunotherapies is in oncology, specifically in treating hematologic malignancies like lymphoma and leukemia.